These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 35547738)

  • 21. Presence of CoV-2 antibody in vitreous humor after Cov-2 infection.
    Li Y; Li J; Li S; Xu Z; Ma W; Wu X; Yan Y; Wang Y; Hu A
    Heliyon; 2024 May; 10(10):e31023. PubMed ID: 38818183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severity.
    Zhang W; Chua B; Selva K; Kedzierski L; Ashhurst T; Haycroft E; Shoffner S; Hensen L; Boyd D; James F; Mouhtouris E; Kwong J; Chua K; Drewett G; Copaescu A; Dobson J; Rowntree L; Habel J; Allen L; Koay HF; Neil J; Gartner M; Lee C; Andersson P; Seemann T; Sherry N; Amanat F; Krammer F; Londrigan S; Wakim L; King N; Godfrey D; Mackay L; Thomas P; Nicholson S; Arnold K; Chung A; Holmes N; Smibert O; Trubiano J; Gordon C; Nguyen T; Kedzierska K
    Res Sq; 2021 Aug; ():. PubMed ID: 34462740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of Interferon-γ Release Assay in the Assessment of T-Cell Immunity to SARS-CoV-2 Antigens in the Cohort of Pediatric Patients with Juvenile Idiopathic Arthritis.
    Kapten K; Orczyk K; Smolewska E
    Children (Basel); 2024 Jun; 11(6):. PubMed ID: 38929315
    [No Abstract]   [Full Text] [Related]  

  • 24. Relationship of various COVID-19 antibody titer with individual characteristics and prediction of future epidemic trend in Xiamen City, China.
    Xu L; Abudunaibi B; Zeng Z; Zhao Y; Wang Y; Guo X; Zhang Y; Li T; Lu W; Tian W; Guo Z; Su C; Chen T
    J Thorac Dis; 2024 Apr; 16(4):2404-2420. PubMed ID: 38738254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of antibody titers in COVID-19 patients with cerebral or pulmonary symptoms and mild symptoms.
    Joudaki N; Ghafouri S; Bavarsad K; Farhadi F; Nasab MA; Afzalzadeh S; Moradzadegan H; Kahyesh RS
    Iran J Microbiol; 2024 Feb; 16(1):124-131. PubMed ID: 38682065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired immune responses in the airways are associated with poor outcome in critically ill COVID-19 patients.
    Barnett CR; Krolikowski K; Postelnicu R; Mukherjee V; Sulaiman I; Chung M; Angel L; Tsay JJ; Wu BG; Yeung ST; Duerr R; Desvignes L; Khanna K; Li Y; Schluger R; Rafeq S; Collazo D; Kyeremateng Y; Amoroso N; Pradhan D; Das S; Evans L; Uyeki TM; Ghedin E; Silverman GJ; Segal LN; Brosnahan SB
    ERJ Open Res; 2024 Jul; 10(4):. PubMed ID: 38978558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area.
    Ng DL; Goldgof GM; Shy BR; Levine AG; Balcerek J; Bapat SP; Prostko J; Rodgers M; Coller K; Pearce S; Franz S; Du L; Stone M; Pillai SK; Sotomayor-Gonzalez A; Servellita V; Martin CSS; Granados A; Glasner DR; Han LM; Truong K; Akagi N; Nguyen DN; Neumann NM; Qazi D; Hsu E; Gu W; Santos YA; Custer B; Green V; Williamson P; Hills NK; Lu CM; Whitman JD; Stramer S; Wang C; Reyes K; Hakim JMC; Sujishi K; Alazzeh F; Pham L; Oon CY; Miller S; Kurtz T; Hackett J; Simmons G; Busch MP; Chiu CY
    medRxiv; 2020 May; ():. PubMed ID: 32511477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Author Correction: Titers of IgG and IgA against SARS-CoV-2 proteins and their association with symptoms in mild COVID-19 infection.
    Abril AG; Alejandre J; Mariscal A; Alserawan L; Rabella N; Roman E; Lopez-Contreras J; Navarro F; Serrano E; Nomdedeu JF; Vidal S
    Sci Rep; 2024 Jul; 14(1):15918. PubMed ID: 38987550
    [No Abstract]   [Full Text] [Related]  

  • 29. COVID-19 and increasing demand for medical oxygen: can impurity be a problem?
    Malik VS; Ravindra K; Singh M
    Environ Sci Pollut Res Int; 2021 Dec; 28(47):66519-66521. PubMed ID: 34535859
    [No Abstract]   [Full Text] [Related]  

  • 30. Predictive values of immune indicators on respiratory failure in the early phase of COVID-19 due to Delta and precedent variants.
    Nagaoka K; Kawasuji H; Takegoshi Y; Murai Y; Kaneda M; Kimoto K; Morimoto S; Tani H; Niimi H; Morinaga Y; Yamamoto Y
    Front Immunol; 2023; 14():1197436. PubMed ID: 37731495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dominant CT Patterns and Immune Responses during the Early Infection Phases of Different SARS-CoV-2 Variants.
    Nagaoka K; Kawasuji H; Takegoshi Y; Murai Y; Kaneda M; Kimoto K; Tani H; Niimi H; Morinaga Y; Noguchi K; Yamamoto Y
    Viruses; 2023 May; 15(6):. PubMed ID: 37376606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IGHG3 hinge length variation was associated with the risk of critical disease and death in a Spanish COVID-19 cohort.
    López-Martínez R; Albaiceta GM; Amado-Rodríguez L; Gómez J; Cuesta-Llavona E; García-Clemente M; Hermida-Valverde T; Enríquez-Rodriguez AI; Hernández-González C; Martínez-Borra J; López-Larrea C; Gil-Peña H; Alvarez V; Coto E
    Genes Immun; 2022 Sep; 23(6):205-208. PubMed ID: 36088493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.
    Sariol CA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina A; Cruz L; Stone ET; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AK; Brien JD; Espino AM
    medRxiv; 2021 Aug; ():. PubMed ID: 34100029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the humoral immune response during COVID-19: guilty or not guilty?
    Yaugel-Novoa M; Bourlet T; Paul S
    Mucosal Immunol; 2022 Jun; 15(6):1170-1180. PubMed ID: 36195658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology.
    Jeremiah SS; Miyakawa K; Ryo A
    J Mol Cell Biol; 2022 Aug; 14(4):. PubMed ID: 35416249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients.
    Tajuelo A; Carretero O; García-Ríos E; López-Siles M; Cano O; Vázquez M; Más V; Rodríguez-Goncer I; Lalueza A; López-Medrano F; Juan RS; Fernández-Ruiz M; Aguado JM; McConnell MJ; Pérez-Romero P
    Front Immunol; 2022; 13():878812. PubMed ID: 35547738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
    Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
    J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.